Evidence map›Paper›PMID 28369074›Full record

ArticlePloS one2017

Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.

Jianhui Zhu, Jing Wu, Xiucong Pei, Zhijing Tan, Jiaqi Shi, David M Lubman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Proteomics in pancreatic cancer.Biomarker research · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Annexin Animal Models-From Fundamental Principles to Translational Research.International journal of molecular sciences · 2021
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Prognostic Significance of Increased Expression of Annexin A10 (ANXA10) in Serous Epithelial Ovarian Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jianhui ZhuDepartment of Surgery, University of Michigan Medical Center, Ann Arbor, MI, United States of America.
Jing WuDepartment of Surgery, University of Michigan Medical Center, Ann Arbor, MI, United States of America.
Xiucong PeiDepartment of Surgery, University of Michigan Medical Center, Ann Arbor, MI, United States of America.
Zhijing TanDepartment of Surgery, University of Michigan Medical Center, Ann Arbor, MI, United States of America.
Jiaqi ShiDepartment of Pathology, University of Michigan School of Medicine, Ann Arbor, Michigan, United States of America.
David M LubmanDepartment of Surgery, University of Michigan Medical Center, Ann Arbor, MI, United States of America.ORCID http://orcid.org/0000-0001-7731-0232
University of Michigan · USShenyang Medical College · CN

Funding

Microsequencing in an Ion Trap/reTOF DeviceR01GM049500 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBMAN, DAVID M. · 1994 to 2016
$3.0M
Serum glycoprotein markers of cancer using an ion mobility/mass spec approachR01CA154455 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUBMAN, DAVID M. · 2011 to 2013
$921k
NCI NIH HHS R01 CA154455NIGMS NIH HHS R01 GM049500
6 · The paper itself

Abstract

Annexins are a multigene family of calcium and phospholipid-binding proteins that play important roles in calcium signaling, cell motility, differentiation and proliferation. Our previous mass spectrometry-based proteomics study revealed that annexin A10 (ANXA10) was uniquely overexpressed in pancreatic CD24+ adenocarcinoma cells that were dissected from clinical PDAC tissues but was absent in CD24- adjacent normal cells. The correlation between ANXA10 expression and the progression of pancreatic cancer remains unknown. In this study, we performed an immunostaining assay to evaluate ANXA10 expression in 155 primary human tissue specimens, including normal pancreas, chronic pancreatitis (CP), pancreatic adenocarcinoma (PDAC), pancreatic intraepithelial neoplasia (PanIN, the most important precursor of PDAC), and intraductal papillary mucinous neoplasm (IPMN). The immunostaining result showed that ANXA10 was significantly overexpressed in PanINs, IPMNs, and PDACs but negative in normal pancreas and the majority of chronic pancreatitis tissues. Statistical analysis revealed that ANXA10 expression was significantly associated with PDAC and its precursor lesions (p<0.0001). Abundant ANXA10 expression was predominantly present in pancreatic ductal epithelial cells of PanINs, IPMNs, and tumor cells of PDACs. Since PDAC develops through a series of PanINs which in turn arise from pancreatic ducts, the consistent overexpression of ANXA10 in ductal epithelial cells in PanINs and PDACs but negative in normal pancreatic ducts suggests that ANXA10 could serve as a potential marker indicating the presence of PDAC at its earliest precancerous stages. Double immunostaining of ANXA10 and CD24 showed that there was a large overlap between these two markers in PDAC and high-grade neoplasia lesions. The statistical analysis showed that the coexpression of ANXA10 and CD24 was significantly correlated with the progression of pancreatic precursor lesions towards PDACs.

Indexed as

AdenocarcinomaAnnexinsBiomarkers, TumorCarcinoma, Pancreatic DuctalCD24 AntigenDisease ProgressionHumansMultigene FamilyPancreasPancreatic DuctsPancreatic NeoplasmsPancreatitis, ChronicAnnexinsANXA10 protein, humanBiomarkers, TumorCD24 AntigenCD24 protein, human

Identifiers

PMID28369074
PMCPMC5378402
OpenAlexW2604234138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.